This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Accelerate oligonucleotide and peptide products from early discovery to late-stage development & commercialization.

The Future of the Oligonucleotide and Peptide Therapeutics Industry

Share this article

In this second edition of the TIDES: Oligonucleotide and Peptide Therapeutics eBook Series, we explore the possible changes in the industry over the next decade. Where are the next goals for oligonucleotide and peptide-based drugs, and what events could be in store for the industry over the next few years?

Join us as we look in depth at survey responses from oligonucleotide and peptide therapeutics professionals around the world on areas such as medical breakthroughs, technology, regulations and diversity in the workplace. We also discuss the progress of macromolecular drugs with industry leaders and ask for their predictions on how the sector will have changed by the year 2030.

The ebook includes:

Click the image at the top of the page or here to explore the ebook.

Share this article

Subscribe to our monthly Peptides & Oligonucleotides newsletter

Get the latest content and updates straight to your inbox

Upcoming event

TIDES Asia: Oligonucleotide & Peptide Therapeutics Virtual Scientific Forum

02 - 05 Mar 2021
Industry leaders and service providers share cutting-edge content and company expertise across the Oligonucleotide, Peptide, mRNA and Drug Delivery spectrum
Go to site